On April 18, 2026, President Donald Trump signed an executive order and announced a federal investment of millions of dollars in ibogaine research. He also directed the FDA to accelerate its review of this medicine. In December of 2025, the state of Texas awarded $50 million to the University of Texas Medical Branch at Galveston, along with the University of Texas Health Houston, to fund a two-year multi-center research trial to evaluate the effects of ibogaine on patients suffering from addiction, traumatic brain injury, and other behavioral health conditions.
For many people, this is the first time they have heard of Ibogaine. What is this medicine, and why are the White House and the state of Texas funding research into its use?
Ibogaine is a psychoactive medicine derived from plants such as Tabernanthe iboga, a rainforest shrub native to the tropical forests of Central and West Africa. Ibogaine possesses psychedelic and dream-inducing effects. For centuries, members of the Bwiti religion have used iboga as a sacrament in rituals to connect with their ancestors.
Ibogaine has a very complex pharmacology and interacts with multiple neurotransmitters, including opioid, serotonin, sigma-1, NMDA, and nicotinic acetylcholine receptors. Its principal metabolite, noribogaine, acts as a serotonin reuptake inhibitor (which is similar to Prozac and other SSRIs) and a κ-opioid receptor agonist (similar to Stadol, which is used to treat migraines).
The subjective experience of ibogaine is unique. The initial phase begins within one to three hours of ingestion and typically consists of vivid waking dreams lasting four to eight hours. A second phase, with onset between eight and 20 hours after dosing, involves heightened intuition, personal insight, and reflection.
A History of Anti-Addictive Use
Purified ibogaine hydrochloride was first introduced in Europe in 1939 under the trade name Lambarène. This medicine was sold in France as an antidepressant and a physical stimulant. Later, a teenager discovered its potential as a treatment for addiction. In 1962, 19-year-old Howard Lotsof and five friends, who were all heroin addicts, noted a reduction in their cravings and withdrawal symptoms after ingesting ibogaine. He then spent the rest of his life promoting the drug’s anti-addictive properties. His advocacy eventually resulted in the National Institute on Drug Abuse creating research programs to explore the anti-addictive potential of this medicine. These were followed by numerous peer-reviewed publications exploring this medicine’s potential benefits as a treatment for substance abuse.
Studies in rodents demonstrated that ibogaine reduces opioid withdrawal symptoms, cocaine self-administration, heroin self-administration, and alcohol dependence. A systematic review confirmed that ibogaine’s activity at multiple receptors may be the key to changing the neuronal circuits that sustain addiction.
Ibogaine for PTSD
More recently, ibogaine has drawn attention as a potential treatment for post-traumatic stress disorder (PTSD), particularly in military veterans. An important study driving much of this momentum came from researchers at Stanford University.
The study enrolled 30 male U.S. Special Operations veterans who had suffered mild to moderate traumatic brain injury (TBI) impairing their functioning, with injuries occurring an average of eight years before the study. Most were experiencing severe psychiatric symptoms: 23 met criteria for PTSD, 15 for major depressive disorder, 15 for alcohol use disorder, and 14 for an anxiety disorder. Over their lifetimes, 19 had experienced suicidal thoughts, and seven had attempted suicide.
These veterans received oral ibogaine with magnesium. The latter reduces the risk of cardiac arrhythmia, associated with this medicine. The results were impressive. Post-treatment assessments demonstrated significant declines in PTSD, anxiety, and depression, along with marked improvements in cognitive function and disability ratings.
Because ibogaine is classified in the U.S. as a Schedule I substance (the same category as heroin), many veterans have been forced to seek treatment abroad. The executive order and the funding from the state of Texas provide support for veterans who are seeking ibogaine treatment in licensed, hospital-grade settings.
Psychedelics Essential Reads
Mechanisms of Action
How does ibogaine produce its wide-ranging effects on addiction, PTSD, and TBI? The answer may lie in its effects on multiple neurotransmitters.
Ibogaine’s antagonism at NMDA (N-methyl-D-aspartate) glutamate receptors is thought to contribute significantly to its rapid interruption of opioid withdrawal and its antidepressant effects. NMDA antagonism reduces excitotoxicity (cell death due to excess glutamate), increases neuroplasticity, and improves mood regulation. Ibogaine shares this mechanism with ketamine, the fast-acting antidepressant that is now widely used in clinical psychiatry.
One of ibogaine’s most intriguing molecular interactions involves its activity at Sigma-1 receptors (S1Rs). These are not classic neurotransmitter receptors but rather are “intracellular chaperone proteins.” These proteins exert numerous effects on cells. In the central nervous system, S1Rs regulate neuroplasticity. This sigma-1 mechanism is similar to how ketamine exerts its antidepressant and neuroprotective effects.
The parallel between these two drugs at the S1R level brings up an important research question: Could sigma-1 receptors provide a common pathway leading to the therapeutic effects of other neuroplastogens? If so, compounds that act on S1R may represent the next frontier in psychiatry.
Cautions Moving Forward
Ibogaine is not without risk. The NIH briefly funded research in the 1990s but discontinued the work due to cardiovascular toxicity. Medical screening, ECG monitoring, and the co-administration of magnesium are important safety measures when taking ibogaine. Individuals with pre-existing cardiac conditions should not take this medicine.
Nevertheless, the combination of veteran advocacy, strong clinical data, and now executive-level political support creates a unique opportunity. The FDA is taking steps to clear the way for the first-ever human trials of ibogaine in the United States, and the state of Texas has launched dedicated research to accelerate clinical development. A $50 million federal commitment, combined with $50 million from the state of Texas, and expedited FDA review, means that the scientific community will have the resources and regulatory runway that were unavailable just a few months ago.
For the hundreds of thousands of veterans, opioid-dependent individuals, and PTSD sufferers who have not responded to conventional treatment, ibogaine may represent what science has long failed to offer: a genuine neurobiological reset of the suffering brain.